← Product Code [LKJ](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ) · K984473 # LIQUICHEK ANA CONTROL, EIA SCREEN, MODEL 205 (K984473) _Bio-Rad · LKJ · Dec 22, 1998 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ/K984473 ## Device Facts - **Applicant:** Bio-Rad - **Product Code:** [LKJ](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ.md) - **Decision Date:** Dec 22, 1998 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5100 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use Liquichek ANA Control, EIA Screen is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the screening of antinuclear antibodies (ANA). ## Device Story Liquichek ANA Control, EIA Screen is an in vitro diagnostic quality control product used in clinical laboratories. It consists of human serum supplemented with preservatives (0.1% sodium azide) and stabilizers. The device is provided in liquid form and is available in negative, positive, and high-positive levels. It is used by laboratory technicians to monitor the accuracy and precision of enzyme immunoassay (EIA) procedures for ANA screening. By running this control alongside patient samples, the laboratory can verify that the assay system is performing within expected parameters, thereby ensuring the reliability of patient test results used in the diagnosis of systemic rheumatic diseases. ## Clinical Evidence no clinical data ## Technological Characteristics Liquid-form quality control material derived from human serum. Contains 0.1% sodium azide as a preservative. Storage requirement is 2-8°C. Open-vial stability is 30 days at 2-8°C. No electronic, mechanical, or software components. ## Regulatory Identification An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues). ## Predicate Devices - Helix Enzyme Immunoassay Antinuclear Antibody Screening Test Kit ([K954723](/device/K954723.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ DEC 22 1998 Image /page/0/Picture/1 description: The image shows the logo for BIO-RAD. The logo is white text on a black background. The text is in a bold, sans-serif font. The logo is simple and recognizable. Laboratories alifornia 92618-2017 ephone: (949) 598-1200 # 510(k) Summary Submitter Bio-Rad Laboratories 9500 Jeronimo Road Irvine, CA (949)598-1285 Fax (949)598-1555 Contact Person Elizabeth Platt Date of Summary Preparation December 14, 1998 Device (Trade & Common Name) Liquichek ANA Control, EIA Screen Classification Name Class II, 82LKJ CFR 866.5100: Antinuclear Antibody, Antigen, Control. Devices to Which Substantial Equivalence is Claimed Helix Enzyme Immunoassay Antinuclear Antibody Screening Test Kit Helix Diagnostics West Sacrament, California K954723 #### Statement of Intended Use Liquichek ANA Control, EIA Screen is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the screening of antinuclear antibodies (ANA). {1}------------------------------------------------ Image /page/1/Picture/0 description: The image shows the logo for BIO-RAD. The logo is in white text on a black background. The text is bold and sans-serif. Bio-Rad Laboratories Diagnostics Group 9500 Jeronimo Road Irvine, California 92618-2017 Telephone: (949) 598-1200 ### Description of the Device Liquichek ANA Control, EIA Screen is prepared from human serum with added preservatives and stabilizers. This product is provided in liquid form for convenience. This product contains 0.1% sodium azide as a preservative. Statement of How Technological Characteristics Compare to Substantial Equivalent Device A table is provided below comparing the similarities between the Bio-Rad Liquichek ANA Control. EIA Screen and the device to which substantial equivalence is claimed. | | Helix Enzyme Immunoassay Antinuclear
Antibody Screening Test Kit | Bio-Rad Liquichek ANA Control,
EIA Screen | |--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------| | Intended Use | A qualitative enzyme immunoassay (EIA) for
screening the presence of antinuclear
antibodies (ANAs) in human serum as an aid
in the diagnosis of certain systemic rheumatic
diseases. | An unassayed quality control
serum for monitoring enzyme
Immunoassay procedures for
the screening of antinuclear
antibodies (ANA). | | Form | Liquid | Liquid | | Matrix | Human Serum | Human Serum | | Levels | Negative, Positive, Cutoff | Negative, Positive, High Positive | | Storage | 2-8°C | 2-8°C | | Analytes | Total ANAs against:
DNA (dsDNA, nDNA)
Histones
SS-A/Ro
SS-B/La
Sm
SmRNP
Scl-70
Jo-1
Centrometric antigens
Sera positive for Immunofluorescent
(IFA) Hep-2 ANAs | Antinuclear antibodies (ANA). | | Open Vial
Claim | Shelf life | 30 Days at 2-8°C | {2}------------------------------------------------ Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 DEC 22 1998 Ms. Elizabeth Platt Staff Requlatory Affairs Representative BIO-RAD LABORATORIES 9500 Jeronimo Road Irvine, CA 92618-2017 Re: K984473 Trade Name: Liquichek ANA Control, EIA Screen Model #205 Requlatory Class: II Product Code: LKJ December 14, 1998 Dated: Received: December 16, 1998 Dear Ms. Platt: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {3}------------------------------------------------ #### Page 2 This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Putman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ Page 1 of 1 · K984473 510(k) Number: Device Name: Liquichek ANA Control, EIA Screen Indications for Use: Liquichek ANA Control, EIA Screen is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the screening of antinuclear antibodies (ANA). ## (Please Do NOT WRITE BELOW THE LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) | (Concurrence of CDRH, Office of Device Evaluation) | | | |----------------------------------------------------|---------|--| | Signature | | | | (Division Sign-Off) | | | | Division of Clinical Laboratory Devices | | | | 510(k) Number | K984473 | | | Prescription Use | Check Mark | OR Over-The Counter Use | |------------------|----------------------------------------------|-------------------------| |------------------|----------------------------------------------|-------------------------| --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ/K984473](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/LKJ/K984473) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com